Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: Comment on the article by Tesfa et al

Arthritis and Rheumatism

Volumn 64, Issue 2, 2012, Pages 596-597

  Besada, Emilio ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; COMORBIDITY; DISEASE COURSE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; HUMANS; NEUTROPENIA; RHEUMATIC DISEASES;

EID: 84856405856     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33428     Document Type: Letter

References (3)

1. Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63: 2209-14.
2. Wolach O, Bairey O, Lahaw M,. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89: 308-18.
3. Furst DE,. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2008; 39: 18-29.